Alcon Inc. (ALC)
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.
Alcon Analysts Increase Their Forecasts After Q2 Results
Alcon Inc. ALC reported mixed second-quarter results, after the closing bell on Tuesday.
Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q2 2024 Earnings Conference Call August 21, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Graham Doyle - UBS Veronika Dubajova - Citi Ryan Zimmerman - BTIG David Adlington - JPMorgan Patrick Wood - Morgan Stanley Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Company Anthony Petrone - Mizuho Group Larry Biegelsen - Wells Fargo Michael Sarcone - Jefferies Issie Kirby - Redburn Atlantic Richard Felton - Goldman Sachs Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Company Brett Fishbin - KeyBanc Capital Markets Operator Greetings and welcome to the Alcon Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
Here is how Alcon (ALC) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Here's Why Alcon (ALC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
